Search results: (10000)
News Subcutaneous Immunoglobulin Substitution in Ig-Naive Patients with PID – Available Efficacy and Safety Data
The prevalence of primary immunodeficiencies (PID) is estimated at 1 : 10,000. Below, we summarize the available findings on the efficacy and safety of subcutaneous immunoglobulin substitution in Ig-naive patients (i.e., without prior immunoglobulin substitution).
News Subcutaneous Immunoglobulin Therapy in Patients with Secondary Immunodeficiency – Real-World Data
Even in patients with secondary immunodeficiency (SID), immunoglobulin substitution can be indicated. Intravenous (IVIG) therapy is considered effective based on studies, but subcutaneous (SCIG) therapy is only based on experiences with patients having primary immunodeficiency (PID). The Italian study presented below, therefore, investigated the efficacy and safety of SCIG in patients with SID.
News Long-term Efficacy, Safety, and Tolerability of Normal Human IgG with Facilitated Absorption in Patients with Humoral Immunodeficiency
The treatment of patients with humoral immunodeficiency is long-term and therefore needs to be not only effective but also safe and well-tolerated. Below, we present the outcomes from an Italian real-world clinical practice study evaluating the efficacy, safety, and tolerability of human immunoglobulin for facilitated subcutaneous administration and patient satisfaction with this therapy.
News Measurement of Serum Trough Levels of IgG as an Adequate and Beneficial Indicator for Assessing the Pharmacokinetics of Subcutaneously Administered Products
For many patients with primary immunodeficiency, lifelong immunoglobulin substitution is essential to reduce the frequency of severe infections. Subcutaneous home administration is better accepted by patients. However, dosing needs to be customized to the patient. The study presented below may help make therapy individualization easier for doctors and more tolerable for patients.
News What to add to amlodipine when it alone is not enough for hypertension?
Treating hypertension is a daily task for not only general practitioners and cardiologists. Polish doctors evaluated the effect of adding bisoprolol on the blood pressure of patients with inadequately controlled hypertension on amlodipine monotherapy in a placebo-controlled AMCOR study.
News Pregabalin Relieves Patients with Central Neuropathic Pain
Treatment of central neuropathic pain, whether caused by spinal cord or cerebral damage, is often lengthy and not always successful. Study results show that pregabalin may be a suitable alternative to traditional preparations, affecting not only pain but also the quality of life of patients.
News Combined Treatment of Chronic Lymphocytic Leukemia in Frail Patients – Results from Real-World Clinical Practice
Treatment of older patients and those with chronic lymphocytic leukemia (CLL) who are not in good physical condition has advanced significantly in recent years. The addition of obinutuzumab to chlorambucil therapy has extended both progression-free survival and overall survival for patients. The authors of the presented study evaluated the efficacy and safety of obinutuzumab in real-world clinical practice.
News Effect of Zolpidem on the Quality of Overnight Sleep in Terms of Episodic Memory Formation
Zolpidem is a non-benzodiazepine hypnotic used for the short-term treatment of insomnia in adults. Previous studies have shown that this gamma-aminobutyric acid (GABA-A) agonist stimulates the occurrence of sleep spindles during short daytime sleep, thereby enhancing episodic memory. A recently published study focused on the effect of zolpidem on memory after overnight sleep.
News Perioperative Thromboprophylaxis in Elderly Patients
Thromboembolic disease (TED) is among the most common causes of death in hospitalized patients and also constitutes a significant portion of complications following surgical procedures. Without prophylaxis, thrombosis would develop in the perioperative period in almost 25% of patients. The risk of TED significantly increases with age, as does mortality. Over 21% of thrombotic complications occur in individuals over 65 years of age, and up to 16% of patients over 80 years old die shortly after being diagnosed with TED. It is crucial to focus on appropriate prevention and prophylaxis of TED in geriatric patients. However, studies have shown that thromboprophylaxis in hospitals in Europe and the USA is inadequate. Reasons may include concerns about increased bleeding during surgical procedures.
News Prognostic Model MSKCC in Patients with Metastatic Renal Carcinoma Treated in 1st Line with Sunitinib
A study by Czech authors published in 2020 demonstrated the usefulness of the MSKCC (Memorial Sloan Kettering Cancer Center) model in the prognostic stratification of patients with metastatic renal carcinoma (mRCC) treated with sunitinib in the 1st line. Additionally, a significant difference was found between the outcomes achieved in patients with intermediate risk who had one or two risk factors.
News Comparison of BEAM and TEAM Conditioning Regimens Before Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Lymphomas
At the beginning of this year, one of the few studies comparing the most commonly used conditioning regimen before autologous hematopoietic stem cell transplantation (ASCT) in patients with lymphomas (BEAM) with a regimen containing thiotepa instead of carmustine (TEAM) was published.
News Perioperative Management in Patients with Atrial Fibrillation Treated with NOACs
The recommended procedures for perioperative management in patients using novel oral anticoagulants (NOACs) stem from the requirement to minimize treatment interruption before and after surgical procedures to reduce the risk of bleeding and thromboembolism. The safety of these regimens in patients with atrial fibrillation was examined in the prospective PAUSE study presented below.
News Critical Conditions in Obstetrics 2022: What is Available in the Czech Republic for Managing Peripartum Life-Threatening Bleeding?
On December 10, 2022, a professional meeting entitled Critical Conditions in Obstetrics 2022 was held in the lecture hall of the new building of the National Museum in Prague. Prof. MUDr. Antonín Pařízek, CSc., from the Department of Gynecology and Obstetrics of the 1st Faculty of Medicine, Charles University, and General University Hospital in Prague, gave a presentation addressing the issue of peripartum life-threatening bleeding (PLTB), the necessities for its management, and provided an overall perspective on the current situation in obstetrics in our country.
News Treatment of Schizophrenia in Light of New Findings
"Mental disorders constitute a significant burden on society," began Assoc. Prof. MUDr. Martin Anders, Ph.D., head of the Psychiatric Clinic at the First Faculty of Medicine, Charles University and General University Hospital in Prague, during his presentation at the psychiatric symposium titled "A Chance for a Better Life with Schizophrenia Diagnosis," held on October 18, 2021, in Prague. His lecture focused on key issues in the treatment of schizophrenia, as well as on one of the recently registered antipsychotics—lurasidone.
News Chronic Thromboembolic Pulmonary Hypertension – Overview of Pathophysiology, Diagnosis, and Treatment
Chronic thromboembolic pulmonary hypertension (CTEPH) is defined by the 2015 ESC/ERS guidelines as symptomatic pulmonary hypertension with persistent defects in lung perfusion despite adequate anticoagulation therapy. Significant values for determining a diagnosis of pulmonary hypertension are a mean pulmonary artery pressure > 25 mmHg. However, this condition remains significantly underdiagnosed, mainly due to its nonspecific symptoms.
News Intestinal Infection of Multi-Resistant NDM-Producing K. pneumoniae in a Patient with NK/T Lymphoma – Case Study
The incidence of NDM-producing Klebsiella pneumoniae is increasing worldwide. NDM beta-lactamase is a significant cause of multidrug resistance in enterobacteria to various antibiotics, including carbapenems. Currently, the most suitable approach for the treatment of intestinal infections caused by NDM-producing K. pneumoniae is considered to be the combination of ceftazidime/avibactam with aztreonam. The following case study also illustrates its use in more complicated cases.
News Use of Inclisiran in a Patient in Secondary Cardiovascular Prevention
Lowering LDL cholesterol (LDL-c) is one of the primary goals for reducing cardiovascular (CV) risk due to its proven mortality reduction. However, many patients with familial hypercholesterolemia or CV disease fail to reach target LDL-c levels even when given the maximum tolerated dose of conventional hypolipidemic treatment. For these patients, inclisiran—a small interfering RNA (siRNA) that lowers cholesterol—offers hope. In the following article, we present a model example of a patient after an acute coronary event for whom starting inclisiran treatment is appropriate.
News Neuroprotective Efficacy and Safety of Vinpocetine in Patients with Acute Ischemic Stroke
A meta-analysis of 4 randomized placebo-controlled studies demonstrated the benefits of vinpocetine in patients with ischemic stroke (iCMP). Administering vinpocetine within 14 days of the onset of the stroke significantly reduced the level of disability and the proportion of those who died or were dependent on others after 1 and 3 months. The results showed benefits in several other parameters and indicated very good tolerability of this drug used to increase cerebral blood flow.
News Quick Relief from Severe AD Symptoms – Dupilumab for Children Aged 6 Years and Older
Children aged 6-12 with severe atopic dermatitis (AD) have very limited treatment options. The studies presented below demonstrate how effective and safe dupilumab, a monoclonal antibody targeting interleukins 4 and 13, is in their case. Since October, this medication is newly covered even for children from 6 years of age.
News How TPO-RA Drugs Fared in Meta-Analyses of Safety and Efficacy in ITP Patients
Meta-analyses regarding the use of thrombopoietin receptor agonists (TPO-RA) evaluated their efficacy and safety in the treatment of primary immune thrombocytopenia over long-term follow-ups. What findings did they uncover?